Education
About Us
Working with TipRanks
Follow Us
NRX Pharmaceuticals (NRXP)
NASDAQ:NRXP
NRXP Stock Chart & Stats
$1.99
-$0.69(-14.70%)
At close: 4:00 PM EST
$1.99
-$0.69(-14.70%)
Day’s Range― - ―
52-Week Range$1.58 - $3.84
Previous CloseN/A
Volume2.07M
Average Volume (3M)475.66K
Market Cap
$53.88M
Enterprise Value$23.07M
Total Cash (Recent Filing)$7.18M
Total Debt (Recent Filing)$347.00K
Price to Earnings (P/E)―
Beta1.22
Next Earnings
Mar 26, 2026EPS Estimate
<0.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.27
Shares Outstanding29,605,150
10 Day Avg. Volume509,446
30 Day Avg. Volume475,656
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)-1.00
Price to Sales (P/S)0.00
P/FCF Ratio-2.18
Enterprise Value/Market Cap0.43
Enterprise Value/Revenue95.32
Enterprise Value/Gross Profit160.19
Enterprise Value/Ebitda-0.61
Forecast
1Y Price Target
$37.67Price Target Upside1792.96% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Product Safety And DifferentiationKETAFREE's preservative-free formulation provides a safety differentiation versus preservative-containing ketamine products, which could encourage adoption by clinics seeking a cleaner labeled option.
Real-world EvidenceA very large real-world dataset on intravenous ketamine outcomes strengthens the supporting evidence and can bolster regulatory discussions and clinician confidence in ketamine-based treatments.
Regulatory ProgressFDA acceptance of the ANDA for KETAFREE and characterization of the filing as substantially complete reduce regulatory uncertainty and create a clearer path toward commercial launch.
Bears Say
Execution And Scaling RiskHOPE network remains in an early growth stage with only a small number of owned centers, creating execution and scaling risk for clinic expansion and revenue ramp.
Financial Performance ShortfallReported revenue and net loss came in below analyst expectations and the absence of financial guidance increases uncertainty about the company's near-term performance.
Profitability And Cash BurnOngoing net and operating losses indicate continued cash burn that could require additional financing or divert resources from development and commercialization efforts.
NRX Pharmaceuticals News
NRXP FAQ
What was NRX Pharmaceuticals’s price range in the past 12 months?
NRX Pharmaceuticals lowest stock price was $1.58 and its highest was $3.84 in the past 12 months.
What is NRX Pharmaceuticals’s market cap?
NRX Pharmaceuticals’s market cap is $53.88M.
When is NRX Pharmaceuticals’s upcoming earnings report date?
NRX Pharmaceuticals’s upcoming earnings report date is Mar 26, 2026 which is in 40 days.
How were NRX Pharmaceuticals’s earnings last quarter?
NRX Pharmaceuticals released its earnings results on Nov 17, 2025. The company reported -$0.27 earnings per share for the quarter, missing the consensus estimate of -$0.02 by -$0.25.
Is NRX Pharmaceuticals overvalued?
According to Wall Street analysts NRX Pharmaceuticals’s price is currently Undervalued.
Does NRX Pharmaceuticals pay dividends?
NRX Pharmaceuticals does not currently pay dividends.
What is NRX Pharmaceuticals’s EPS estimate?
NRX Pharmaceuticals’s EPS estimate is <0.01.
How many shares outstanding does NRX Pharmaceuticals have?
NRX Pharmaceuticals has 29,605,150 shares outstanding.
What happened to NRX Pharmaceuticals’s price movement after its last earnings report?
NRX Pharmaceuticals reported an EPS of -$0.27 in its last earnings report, missing expectations of -$0.02. Following the earnings report the stock price went down -15.261%.
Which hedge fund is a major shareholder of NRX Pharmaceuticals?
Currently, no hedge funds are holding shares in NRXP
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
NRX Pharmaceuticals Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$37.67 (1792.96% Upside)
$37.67 (1792.96% Upside)
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.6%
Last 30 Days ▼ 3.2%
Last 30 Days ▼ 3.2%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
164.80%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-8.09%
Trailing 12-Months
Company Description
NRX Pharmaceuticals
NRX Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. Its products include ZYESAMI, an investigational drug that has completed a Phase IIb/III clinical study for COVID-19 related respiratory failure; and NRX-100 and NRX-101 oral therapeutics for the treatment of bipolar depression in patients with acute suicidal behavior/ideation and sub-acute suicidal ideation and behavior. The company was founded in 2015 and is based in Wilmington, Delaware.
NRXP Earnings Call
Q3 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call highlighted significant advancements in drug development and clinical progress, along with strong financial positioning and strategic expansions in clinic operations. However, there were challenges such as increased operational losses and limited initial revenue. Despite these challenges, the overall sentiment is optimistic due to the transformative progress and potential for substantial growth.View all NRXP earnings summariesNRXP Stock 12 Month Forecast
Average Price Target
$37.67
▲(1792.96% Upside)
Technical Analysis
CervoMed
―
Coeptis Therapeutics Holdings
―
Werewolf Therapeutics
―
OKYO Pharma Limited Sponsored ADR
―
CAMP4 Therapeutics Corporation
―
Ownership Overview
12.75%
Insiders
1.99% Mutual Funds
8.27% Other Institutional Investors
73.63% Public Companies and Individual Investors